[In-vivo activation of the p53 pathway by small-molecule antagonists of MDM2].
Shinohara
Tokuyuki
T
Shinohara_Tokuyuki@takeda.co.jp
Uesugi
Motonari
M
D000818:Animals; D000970:Antineoplastic Agents; D017209:Apoptosis / Q000187:drug effects / Q000235:genetics; D015195:Drug Design; D015870:Gene Expression / Q000187:drug effects; D005786:Gene Expression Regulation; D006801:Humans; D007093:Imidazoles / Q000302:isolation & purification / Q000494:pharmacology / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D010879:Piperazines / Q000302:isolation & purification / Q000494:pharmacology / Q000627:therapeutic use; D054730:Protein Interaction Domains and Motifs; D051736:Proto-Oncogene Proteins c-mdm2 / Q000037:antagonists & inhibitors / Q000502:physiology; D016159:Tumor Suppressor Protein p53 / Q000502:physiology
D000970:Antineoplastic Agents; D007093:Imidazoles; D010879:Piperazines; D016159:Tumor Suppressor Protein p53; C482203:nutlin 1; D051736:Proto-Oncogene Proteins c-mdm2